Alimera Sciences Stock (NASDAQ:ALIM), Trade Ideas

Alimera Sciences

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.

News

Penny Stocks

Small Cap

Trading Ideas

AIRS

ALIM

GETY

HOFV

LUNR

MLTX

PXMD

RMBL

TORO

WLDS

Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move.

High short interest and steep borrowing costs are among the common traits that could lead to a short squeeze.

10 Short Squeeze Stocks To Watch: Getty Images, Intuitive Machines, Wearable Devices &amp; More

Intraday Update

Markets

Movers

AMTX

ARTNA

ATNF

AVTX

CINT

CTLT

CVCO

EFSH

ELBM

ELEV

FTCH

GLOB

GTEC

IFBD

LSDI

MGRM

MULN

NUTX

PHIO

QBTS

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SLQT

SOND

SONN

STXS

UTRS

VAPO

WKEY

WLMS

XELA

ZUMZ

ZVSA

Gainers


	Monogram Orthopaedics Inc. (NASDAQ: MGRM) shares climbed 148.3% to $29.18 after jumping 62% on Thursday. Monogram Orthopaedics raised $17,216,147 through the sale of 2,374,641 shares of its Class A Common Stock priced at $7.25 per share.


Why Foot Locker Shares Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Pre-Market Outlook

CMND

EGIO

ENVB

FFIE

HILS

KPLT

Why DXC Technology Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket

Alimera Sciences Inc

ALIMCO FINANCIAL CORP by Alimco Financial Corporation

Alimco Financial Corp

ALIMENTATION COUCHE-TARD by Alimentation Couche-Tard Inc.

Alimentation Couche-Tard Inc

Maxim Group analyst Naz Rahman initiates coverage on Alimera Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIM#NASDAQ">ALIM</a>) with a Buy rating and announces Price Target of $10.

Price Target

Initiation

Analyst Ratings

Maxim Group Initiates Coverage On Alimera Sciences with Buy Rating, Announces Price Target of $10

Biotech

General

Alimera Announces First Patient Randomized In Radiation Retinopathy Trial Being Conducted By The DRCR Retina Network

HC Wainwright &amp; Co. analyst Yi Chen maintains Alimera Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIM#NASDAQ">ALIM</a>) with a Buy and raises the price target from $5 to $6.

HC Wainwright & Co. Maintains Buy on Alimera Sciences, Raises Price Target to $6

Earnings

Guidance

Alimera Sciences Expects 2024 Revenue Over $105M Vs. $103.66M Consensus, And Greater Than 20% Adjusted EBITDA Margin

Alimera Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIM#NASDAQ">ALIM</a>) reported quarterly losses of $(0.07) per share. This is a 87.04 percent increase over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $26.31 million which beat the analyst consensus estimate of $24.34 million by 8.08 percent. This is a 87.51 percent increase over sales of $14.03 million the same period last year.

Alimera Sciences Q4 EPS $(0.07) Up From $(0.54) YoY, Sales $26.31M Beat $24.34M Estimate

AFCG

AOUT

ARBE

ARCT

ARHS

ASLE

ASPS

AVGO

BBAI

BBCP

BILI

BITF

BNED

BURL

CHMI

CIEN

CLAR

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

COOK

COST

CTOS

DBVT

DLTH

DOCU

DOMO

DSGR

DXPE

ELUT

EOLS

EVGN

EYPT

FCEL

FNKO

GEVO

GIFI

GRND

GRNT

GWRE

HBIO

ISDR

JYNT

LCTX

LMNR

LOCO

LUMO

LVRO

METC

MGNX

MKFG

MRVL

NAPA

NCSM

NDLS

NEPH

NINE

ONCT

ONCY

OPFI

OPTN

OWLT

PBPB

PHAT

PMTS

PRCH

PowerShares Dynamic Industrials Sector Portfolio

PROF

PRTS

PSFE

RDVT

REAX

REFR

RWAY

SDPI

SGHT

Earnings Scheduled For March 7, 2024

Alimera Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIM#NASDAQ">ALIM</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-07. Here's what investors need to know before the announcement.
Analysts estimate that Alimera Sciences will report an earnings per share (EPS) of $0.00. 
Alimera Sciences bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.00, which was followed by a 2.92% drop in the share price the next day.
Here's a look at Alimera Sciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.06</td>
<td>0.06</td>
<td>-0.51</td>
<td>-0.33</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.06</td>
<td>-0.46</td>
<td>-0.71</td>
<td>-0.54</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>-2.0%</td>
<td>15.0%</td>
<td>18.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709751721_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Alimera Sciences were trading at $3.78 as of March 05. Over the last 52-week period, shares are up 92.42%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ALIM/earnings">To track all earnings releases for Alimera Sciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Alimera Sciences's Earnings

Alimera Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIM#NASDAQ">ALIM</a>) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance recommending that patients with a natural lens (phakic patients) being treated for chronic diabetic macular edema (DME) have access to ILUVIEN 190 microgram intravitreal implant in applicator (fluocinolone acetonide).
"This is great news that NICE has issued final draft guidance to make ILUVIEN available for phakic patients suffering with chronic DME," said Rick Eiswirth, President and Chief Executive Officer of Alimera. "These patients represent up to 75% of the overall DME population in the United Kingdom&#x2A; who will now potentially have access to ILUVIEN to help control the recurrence of the disease for up to 36 months. We look forward to the publication of Final Guidance shortly."
NICE is recommending on label access to ILUVIEN as an option for treating visual impairment caused by chronic DME in phakic eyes. The Final Guidance for ILUVIEN in phakic eyes will be issued after February 22, 2024, when it will be combined with the previous NICE recommendation for patients with a pseudophakic lens and re-issued as a single updated guidance from NICE.
NHS England has agreed with the Integrated Care Boards (ICB's) to provide funding to implement this guidance 30 days after publication. NHS Wales will usually fund within 2 months of the final draft guidance.
&#x2A;From the UK Macular Society submission included in the NICE TA824 review, page 9.

The UK National Institute For Health And Care Excellence Issues Final Draft Guidance To Provide Patients With A Natural Lens Being Treated For Chronic Diabetic Macular Edema Access To ILUVIEN

Alimera Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIM#NASDAQ">ALIM</a>) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces that it has completed enrollment for the company's Synchronicity Study, a prospective, open-label clinical study evaluating the safety and efficacy of YUTIQ (fluocinolone acetonide intravitreal implant 0.18mg) in the treatment of chronic non-infectious uveitis and related intraocular inflammation.
"We are pleased to reach the enrollment target for this Phase 4 open-label study only a few short months after our acquisition of YUTIQ," said Rick Eiswirth, Alimera's President and Chief Executive Officer. "We look forward to the initial readout from this study in the second half of next year to provide retina specialists with a broader sense of the utility of fluocinolone acetonide in a durable intravitreal implant across a variety of patients with chronic non-infectious uveitis affecting the posterior segment (NIU-PS). This could potentially benefit both YUTIQ in the United States and ILUVIEN in Europe and the Middle East, where it is approved to treat chronic NIU-PS."
About Synchronicity
The Synchronicity Study is a multicenter, open label study evaluating YUTIQ in chronic inflammation. The Synchronicity Study currently has enrolled 110 patient eyes in approximately 25 sites around the U.S.
Patients who meet the entry criteria receive YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg as an intravitreal injection in the designated study eye. The treatment period is 36 months, with data capture for this study being the first 24 months of YUTIQ drug treatment.
The primary outcome measure for the SYNCHRONICITY Study is the mean change from baseline in BCVA letter score in the study eye measured by EDTRS at Month 6 and the mean change from baseline central subfield thickness at Month 6. Key secondary endpoints include time to recurrence of non-infectious inflammation in the study eye, presence of vascular leakage at Months 1, 3, 6, 12, 18, and 24, proportion of subjects with resolution of macular edema at Months 1, 3, 6, 12, 18, and 24, mean change from baseline in BCVA letter score at Day 14 and at Months 1, 3, 12, 18, and 24, and mean change from baseline in CST at Months 1, 3, 12, 18, and 24. Full study details are available at <a href="https://clinicaltrials.gov/">https://clinicaltrials.gov</a>.
About YUTIQ
YUTIQ is a sustained release fluocinolone acetonide intravitreal implant injected into the back of the eye using CONTINUOUS MICRODOSING&#x2122; technology, which is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months, to reduce the recurrence of disease and enable patients to maintain vision longer with fewer injections. YUTIQ helps provide CONTINUOUS CALM&#x2122; by reducing recurrence of inflammation in the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. For more information, please visit <a href="http://www.yutiq.com/">www.YUTIQ.com</a>
About Non-Infectious Uveitis Affecting the Posterior Segment (NIU-PS)
It is a diverse group of non-infectious uveitic inflammatory conditions that can affect the posterior segment of the eye. NIU-PS can affect people of all ages, producing swelling and destroying eye tissues, which can lead to severe vision loss and blindness and is a leading cause of working age blindness in many countries. Patients with NIU-PS are typically treated with systemic steroids, which are effective, but over time frequently lead to serious side effects, ranging from acne, weight gain, sleep and mood disorders to hypertension and osteoporosis that can limit effective dosing. Patients then often progress to steroid-sparing therapy with systemic immune suppressants or biologics, which may also have severe side effects, including an increased risk of cancer and infection.

Alimera Completes Recruitment For The Synchronicity Study

Management

Alimera Sciences Appoints Elliot Maltz As CFO Effective Immediately; Succeeds Russell Skibsted

Russell Skibsted, Chief Financial Officer &amp; SVP at Alimera Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIM#NASDAQ">ALIM</a>), reported a large acquisition of company stock options on November 28, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001267602/000110465923121644//Archives/edgar/data/1267602/000110465923121644/0001104659-23-121644-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Skibsted, Chief Financial Officer &amp; SVP at Alimera Sciences, a company in the Health Care sector, was just awarded stock options worth 50,000 shares of ALIM. The options give Skibsted the right to buy the company's stock at $3.38 per share.
Alimera Sciences shares are trading down 11.25% at $3.03 at the time of this writing on Wednesday morning. Since the current price is $3.03, this makes Skibsted's 50,000 shares worth $151,325.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001267602">Check Out The Full List Of Alimera Sciences's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Chief Financial Officer & SVP at Alimera Sciences Acquires Company Stock Options Worth 50,000 Shares

Philip Ashman, Chief Operating Officer &amp; SVP at Alimera Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIM#NASDAQ">ALIM</a>), reported a large acquisition of company stock options on November 28, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001267602/000110465923121636//Archives/edgar/data/1267602/000110465923121636/0001104659-23-121636-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Ashman, Chief Operating Officer &amp; SVP at Alimera Sciences, a company in the Health Care sector, was just awarded stock options worth 147,000 shares of ALIM. The options give Ashman the right to buy the company's stock at $3.38 per share.
Alimera Sciences shares are trading down 11.25% at $3.03 at the time of this writing on Wednesday morning. Since the current price is $3.03, this makes Ashman's 147,000 shares worth $444,895.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001267602">Check Out The Full List Of Alimera Sciences's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Chief Operating Officer & SVP at Alimera Sciences Acquires Company Stock Options Worth 147,000 Shares

David Holland, Chief Marketing Officer &amp; SVP at Alimera Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIM#NASDAQ">ALIM</a>), reported a large acquisition of company stock options on November 28, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001267602/000110465923121641//Archives/edgar/data/1267602/000110465923121641/0001104659-23-121641-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Holland, Chief Marketing Officer &amp; SVP at Alimera Sciences, a company in the Health Care sector, was just awarded stock options worth 100,000 shares of ALIM. The options give Holland the right to buy the company's stock at $3.38 per share.
Alimera Sciences shares are trading down 11.25% at $3.03 at the time of this writing on Wednesday morning. Since the current price is $3.03, this makes Holland's 100,000 shares worth $302,650.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001267602">Check Out The Full List Of Alimera Sciences's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Alimera Sciences Chief Marketing Officer & SVP Awarded $302K Worth of Stock Options

Alimera Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIM#NASDAQ">ALIM</a>) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that clinical data for ILUVIEN&#xAE; (fluocinolone acetonide intravitreal implant) 0.19 mg taken from the three-year, phase IV, real-world observational PALADIN study evaluating the long-term safety of ILUVIEN for patients with diabetic macular edema, will be featured in three posters and a presentation on behalf of the PALADIN Investigators, during the American Academy of Ophthalmology's 127th Annual Meeting being held in San Francisco from November 3-6, 2023.
Presentation: Pauline Merrill, MD "0.19 mg Fluocinolone Acetonide Implant Improves Vision and Treatment Burden in Patients with DME: The PALADIN Study" (Sunday November 5, 4:45 p.m. PST)
Posters: David Chin-Yee, MD "Outcomes in Eyes Requiring IOP Lowering Surgery After Treatment with the 0.19 Fluocinolone Acetonide Implant for DME: The PALADIN Study" (Poster Session PO562)
Daniel Kiernan, MD "0.19 mg Fluocinolone Acetonide Implant Leads to Superior DME Treatment Outcomes in Eyes with Better Baseline Visual Acuity (≥20/40)" (Poster Session PO522)
Mathew MacCumber, MD, PhD Control of Retinal Thickness Variability Improves Vision Following the 0.19mg Fluocinolone Acetonide Implant in Patients with DME" (Poster Session PO518)

Alimera Announces Scientific Data Highlighting ILUVIEN To Be Presented At The American Academy Of Ophthalmology

Alimera Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIM#NASDAQ">ALIM</a>) reported quarterly losses of $(0.06) per share. This is a 92 percent increase over losses of $(0.75) per share from the same period last year. The company reported quarterly sales of $23.36 million which beat the analyst consensus estimate of $22.72 million by 2.83 percent. This is a 71.82 percent increase over sales of $13.60 million the same period last year.

Alimera Sciences Q3 EPS $(0.06) Vs $(0.75) Last Year, Sales $23.36M Beat $22.72M Estimate

Alimera Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIM#NASDAQ">ALIM</a>) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that clinical data for ILUVIEN&#xAE; (fluocinolone acetonide intravitreal implant) 0.19 mg and YUTIQ&#xAE; (fluocinolone acetonide intravitreal implant) 0.18 mg will be featured in five presentations during the Retina Society's 56th Annual Scientific Meeting being held in New York City from October 11-14, 2023. &nbsp;
Presentations: Pouya Dayani, MD "CALM: 24-Month Efficacy and Safety Outcomes From a Phase 4 Registry Study for Patients with Chronic Non-Infectious Posterior Segment Uveitis Treated with a 0.18 mg Fluocinolone Acetonide Intravitreal Insert" (Wednesday October 11, 4:17 p.m.)
Mathew MacCumber, MD, PhD "Fluocinolone Acetonide (FAc) 0.19mg Implant Improves Vision and Treatment Burden in Patients with Diabetic Macular Edema: The PALADIN Study" (Friday October 13, 2:30 p.m.)
Seenu Hariprasad, MD "0.19 mg Fluocinolone Acetonide (FAc) Implant Leads to Superior Visual-, Anatomical-, and Treatment Burden-Related Outcomes in Eyes with Better Baseline Visual Acuity (≥20/40)" (Friday October 13, 2:34 p.m.)
Fernando Arevalo, MD "Long-Term Outcomes in Eyes Requiring IOP Lowering Surgery After Treatment with the 0.19 Fluocinolone Acetonide Implant for DME: The PALADIN Study" (Friday October 13, 2:40 p.m.)
Christopher Riemann, MD "Long-Term Outcomes of Eyes Requiring IOP Lowering Treatment (IOPT) Post Administration of the 0.19mg Fluocinolone Acetonide (FAc) Implant for Diabetic Macular Edema (DME)" (Friday October 13, 2:43 p.m.)
About ILUVIEN and YUTIQ <a href="https://www.globenewswire.com/Tracker?data=qThKTEfvxhn2434xga_6dWZxcaWln1Ob1nOckCwRg2FsP71-4JONL-tbDbTIHp5C7CT5LoLZCfNpJzIzT59Iyg==">www.ILUVIEN.com</a>&nbsp;&nbsp;&nbsp; <a href="https://www.globenewswire.com/Tracker?data=qfQfWPsmm6C0q459NWhZc6qffVlunVhLyJtb3AnrGYeLar6g3uVoUO86RY0_R7LyznOwrXqkFJ8ISkkOC0K-jA==">www.YUTIQ.com</a>
Both ILUVIEN and YUTIQ are sustained release intravitreal implants injected into the back of the eye. Both utilize CONTINUOUS MICRODOSING&#x2122; technology, which is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months, to reduce the recurrence of disease. ILUVIEN enables patients to maintain vision longer with fewer injections and is used to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. YUTIQ maintains vision longer by reducing the recurrence of inflammation and is used for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
About Diabetic Macular Edema (DME) DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy found that over a 10-year period approximately 19% of people with diabetes included in the study were diagnosed with DME.

Alimera Announces Multiple Presentations Highlighting ILUVIEN And YUTIQ Data At Retina Society Annual Congress

Adam Morgan, Board Member at Alimera Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIM#NASDAQ">ALIM</a>), reported a large acquisition of company stock options on October 4, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001267602/000092189523002311//Archives/edgar/data/1267602/000092189523002311/0000921895-23-002311-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that Morgan, Board Member at Alimera Sciences, a company in the Health Care sector, was just awarded stock options worth 50,000 shares of ALIM. The options give Morgan the right to buy the company's stock at $2.99 per share.
Alimera Sciences shares are trading down 4.14% at $3.01 at the time of this writing on Thursday morning. Since the current price is $3.01, this makes Morgan's 50,000 shares worth $150,500.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001267602">Check Out The Full List Of Alimera Sciences's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Board Member at Alimera Sciences Acquires Company Stock Options Worth 50,000 Shares

<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1267602/000126760223000116/alim-20231002x8k.htm" title="https://www.sec.gov/ix?doc=/Archives/edgar/data/1267602/000126760223000116/alim-20231002x8k.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/1267602/000126760223000116/alim-20231002x8k.htm</a>

Health Care

On October 3, 2023, Alimera Sciences Appointed Jason Werner As The Company's Chief Operating Officer, Effective October 2: 8K

Within the last quarter, Alimera Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIM#NASDAQ">ALIM</a>) has observed the following analyst ratings: 
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
These 4 analysts have an average price target of $5.75 versus the current price of Alimera Sciences at $3.41, implying upside.
Below is a summary of how these 4 analysts rated Alimera Sciences over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
<img src="https://www.benzinga.com/files/images/story/2023/1692039615_0.png" alt="price target chart" />
This current average has decreased by 14.81% from the previous average price target of $6.75. 
<a href="https://www.benzinga.com/quote/ALIM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Alimera Sciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h1>Analyst Ratings: What Are They?</h1>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings for Alimera Sciences

HC Wainwright &amp; Co. analyst Yi Chen reiterates Alimera Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALIM#NASDAQ">ALIM</a>) with a Buy and maintains $5 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Alimera Sciences, Maintains $5 Price Target

Alimera Sciences (ALIM) has released an update to notify the public and investors about its officers. Alimera Sciences, Inc. has launched the 2024 ...

Alimera Sciences Launches 2024 Equity Inducement Plan

Alimera Sciences Inc (ALIM) is around the top of the Drug Manufacturers - Specialty and Generic industry according to InvestorsObserver. ALIM received an overall rating of 70, which means that it scores higher than 70 percent of all stocks. Alimera Sciences Inc also achieved a score of 93 in the Drug Manufacturers - Specia

Should You Sell Alimera Sciences Inc (ALIM) in Drug Manufacturers - Specialty & Generic Industry?

Alimera Sciences Q4 2023 Earnings Preview

Alimera Sciences GAAP EPS of -$0.07, revenue of $26.31M beats by $1.97M

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alimera (ALIM – Research Report) and Avid Bioservice...

Analysts Are Bullish on Top Healthcare Stocks: Alimera (ALIM), Avid Bioservices (CDMO)

Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript